1 in 3 or 35 million people above the age of 50 in the US choose not be screened for colorectal cancer1. This year alone, about 140,000 new cases of colorectal cancer will be diagnosed and costs of approximately $ 14 billion will be incurred to the healthcare system. Outside the US, the compliance for colorectal cancer screening is even lower. As a result, 600,000 people globally die of this disease every year2.
Clear focus on the US market
In an effort to focus the activities of the company on one of the largest commercial opportunities in the molecular diagnostics industry, Epigenomics has increasingly shifted the focus of its activities for the introduction of Septin9 testing to the U.S.
On the commercialization side, there were further positive developments by Epigenomics and its North American laboratory partners in 2011.
- In November, ARUP Laboratories presented exciting new study results for its Septin9 blood test for colorectal cancer (Septin9 LDT) at the annual meeting at Association for Molecular Pathology
- In aggregate, more than 26.000 people in the U.S. and Canada received a Septin9 test in 2011, mainly by our partner Quest Diagnostics.
in the U.S.A. and Canada. Current LDT partners represent potential future customers for Epigenomics once Epi proColongains approval by FDA.
Realignment of the marketing and sales strategy in Europe
Sales revenues from Epi proColon 2.0 CE and the implementation of the adapted marketing strategy.
With the goal of extending the availability of Epi proColon, during 2011 Epigenomics signed new distribution agreements with partners in Spain and South Africa.
The announcement of the positive clinical validation data for the certification of the second generation product in Europe triggered positive reactions from customers. Epi proColon 2.0 CE was subsequently introduced into the European market and is now available through Epigenomics and its distributors.
- Centers for Disease Control. US Health and Data Statistics 2009.